MyCartis to engage in point-of-need testing with the ANTELOPE Dx platform technology

Today, MyCartis announces the addition of a point-of-need testing technology, ANTELOPE Dx, to complement its immuno-assay technology offering.
MyCartis has developed immunoassay technology, DMAT® [1], which is integrated in its real-time immuno-diagnostic EVALUTION® platform. DMAT® delivers an unmatched combination of features, covering multiplexing, assay speed and analytical performance, together with the unique ability to qualify immune responses directly.

MyCartis continues to innovate in next generation immunodiagnostic technologies and as such it will engage in a novel point-of-need diagnostic solution named ANTELOPE Dx.
ANTELOPE Dx is an immuno-diagnostic platform in development, that aims to offer clinical lab performance with the ease-of-use of a pregnancy test at a consumer price tag. The technology originated from UGent, Belgium, under supervision of Professor Peter Bienstman, in the Photonics Research Group of Professor Roel Baets, with Jan-Willem Hoste as lead investigator. Jan-Willem Hoste will play a crucial role in the further development of the technology, the platform and the test menu.
The platform consists of a disposable cartridge and a very small reader module. The heart of the technology is a silicon photonic chip inside the cartridge. This single use test can measure different parameters simultaneously targeting the quality of the large clinical analyzers. ANTELOPE Dx will make it possible to get clinical grade diagnostics at home or at the doctor’s office within minutes.


Peter Bienstman, professor at Ghent University, comments “This technology has been in development for more than ten years, and we’re excited and proud that ANTELOPE Dx and MyCartis will partner up to bring this point-of-need testing to the patient.”


Jan-Willem Hoste, ANTELOPE Dx lead in MyCartis, adds: “Both digital health solutions and point-of-care diagnostics are evolving rapidly and offer solutions for decentralized healthcare, each in their own way. We believe the Antelope technology will connect the dots: affordable and easy to use, yet without compromising on quality.”


“We are very excited that we can contribute to bringing actionable clinical diagnostic guidance closer to the patient”, says Hilde Windels, CEO of MyCartis “We will work hard with a very dedicated, experienced team to provide a solution which is affordable, fast and reliable, three necessary ingredients to be at the forefront of next generation point-of-need testing.”


The menu of tests that will be introduced to the market will truly address unmet needs. The first test is already in development and will be a direct-to-consumer test that will provide an immediate and easy to read result about sexually transmitted diseases (STDs).
STDs are infections caused by organisms that can be transmitted from one person to another through sexual activity and intimate contact. The U.S. Center for Disease Control and Prevention (CDC) estimates that there are almost 20 million new STD cases each year in the U.S alone. Half of the cases occur in the population between 15 and 24 years. Research shows that embarrassment often prevents people from engaging with the healthcare system. Indeed, questioning over 1650 young adults in The Netherlands and Belgium shows that 63% would feel more comfortable with a self-test solution, such as ANTELOPE Dx[2].
The second test will determine whether a patient has an acute bacterial or viral infection. Bacterial and viral infections are often clinically indistinguishable, leading to antibiotic overuse and contributing to the spread of antibiotic resistance, one of the biggest threats to global health according the WHO. The test will guide both doctor and patient towards required treatment in less than 10 minutes during the doctor’s visit.
Other applications in the pipeline relate to therapeutic drug monitoring at home and follow-up of heart disease patients.


1 DMAT®: Dynamic multi-analyte technology
2 Study executed in 2017 by Ugent



MyCartis has developed the immunoassay technology, DMAT®, which is integrated in its real-time immuno-diagnostic platform EVALUTION®. DMAT® delivers an unmatched combination of features, covering multiplexing, assay speed and analytical performance, together with the unique ability to measure antibody binding strength and hence qualify immune responses directly.
The multiplex DMAT® technology can also be integrated in other platforms (new and existing), meeting specific throughput, random access and other requirements of selective applications.
EVALUTION® is a multiplex platform, using a 16-channel disposable cartridge. It is currently used in the Life Sciences research context and is validated for many multiplex assays in-house and with partners.
Key active areas for MyCartis are serology applications (allergy, auto-immunity, infectious diseases and vaccinology) and the rapid and real-time objective assessment of donor organ fitness.
MyCartis’ Quality Management System is ISO 13485 certified by TÜV Rheinland, allowing CE-IVD developments. MyCartis is a privately held company and employs about 30 people.



Interested in a regular update of the Life Sciences and biotech sector in Flanders?